The aim of this study was to investigate the sensitivity of the same panel of pancreatic cancer cell lines to treatment with an IGF-IR TKI, NVP-AEW541[20], when used alone or in combination with afatinib, anti-EGFR mAb ICR62 or gemcitabine. The gene discussed is EGFR; the disease is familial pancreatic carcinoma.